| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/12/2006 | US20060009482 Screening method for identifying compounds that selectively induce interferon alpha |
| 01/12/2006 | US20060009475 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 01/12/2006 | US20060009474 substituted amino pyrimidine derivatives useful in the treatment or prevention of viral infections, in particular against human immunodeficiency virus (HIV), which is the aetiological agent of acquired immune deficiency syndrome (AIDS) in humans |
| 01/12/2006 | US20060009470 Method for specifically potentiating N-type Ca2+ channel activity |
| 01/12/2006 | US20060009465 Treatment of sleep disorders using sleep target modulators |
| 01/12/2006 | US20060009437 A medicament containing formoterol or formoterol fumarate and/or mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease; inhalable form in an atomizable composition or in a dry powder |
| 01/12/2006 | US20060009426 Pharmaceutical compositions comprising calcitriol and a clobetasol propionate |
| 01/12/2006 | US20060009416 Vitamin B6, pyridinoline, 3-hydroxypyridine, or an N-alkyl-3-hydroxypyridine; sunscreen agents |
| 01/12/2006 | US20060009414 Protecting a muscarinic acetylcholine receptor in patient; prevent tissue damage, increasing the efficacy of a therapeutic agent |
| 01/12/2006 | US20060009413 Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions |
| 01/12/2006 | US20060009412 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
| 01/12/2006 | US20060009407 Administering arginine, lysine; cardiovascular disorder therapy |
| 01/12/2006 | US20060009399 Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| 01/12/2006 | US20060009390 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 01/12/2006 | US20060009387 Apo-2 ligand/trail formulations |
| 01/12/2006 | US20060008889 Phosphatase specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative, autoimmune, muscular and graft vs. host diseases |
| 01/12/2006 | US20060008804 Marker genes |
| 01/12/2006 | US20060008802 Method for the identification of inhibitors of the binding of are-containing mrna and a hur protein |
| 01/12/2006 | US20060008797 Peptide that that binds to microglial receptors; may be conjugated to a carrier molecule that increases transport across the blood-brain barrier; treating neurological effects of cerebral ischemia or cerebral inflammation |
| 01/12/2006 | US20060008544 Methods for enhancing antioxidant enzyme activity and reducing C-reactive protein levels |
| 01/12/2006 | US20060008543 Forming antioxidant-promoting composition by mixing bacopa monniera extract having 45& bacosides or greater, silybum marianum extract, Withania somnifera powder, Camellia sinensis powder having 98% polyphenols and 45% epigallocatechin gallate, and turmeric extract having 95% curcumin |
| 01/12/2006 | US20060008532 Complexes of protein crystals and ionic polymers |
| 01/12/2006 | US20060008511 Probiotic products for pet applications |
| 01/12/2006 | US20060008509 synergistic efficacy; polar lipid supplement, a soluble fiber, and a nutricine such as threonine |
| 01/12/2006 | US20060008459 Combination therapy of respiratory diseases using antibodies |
| 01/12/2006 | US20060008453 Methods and compositions for preventing and treating sensitive and dry skin |
| 01/12/2006 | DE102004030880A1 Methode zur Behandlung von Diabetes Method for the treatment of diabetes |
| 01/12/2006 | CA2572872A1 Tissue factor production inhibitor |
| 01/12/2006 | CA2572751A1 Pegylated interferon alpha-1b |
| 01/12/2006 | CA2572129A1 Viral particle-like construct and method of forming the same under physiological conditions |
| 01/12/2006 | CA2571822A1 Preventive or therapeutic agent for vascular intimal proliferative disease |
| 01/12/2006 | CA2571598A1 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/11/2006 | EP1615032A1 Method of detecting onset risk of encephalitis or encephalopathy |
| 01/11/2006 | EP1614432A2 Method for treating amyloidosis |
| 01/11/2006 | EP1614430A2 Compositions containing anti-acne agents and the use thereof |
| 01/11/2006 | EP1614428A1 Drug for preventing or treating angiogenic eye diseases |
| 01/11/2006 | EP1614418A1 use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia |
| 01/11/2006 | EP1614416A2 Method for treating amyloidosis |
| 01/11/2006 | EP1613628A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 01/11/2006 | EP1613339A2 Anti-fungal peptidomimetics |
| 01/11/2006 | EP1613327A2 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug |
| 01/11/2006 | EP1613325A1 Combinations comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or anxiety |
| 01/11/2006 | EP1613324A2 Methods for the treatment of pain comprising opioid antagonists |
| 01/11/2006 | EP1613320A1 Dosage forms comprising ag013736 |
| 01/11/2006 | EP1613308A1 Novel methods for the treatment of cancer |
| 01/11/2006 | EP1613302A2 Preserved and stable compositions containing peptide copper complexes and methods related thereto |
| 01/11/2006 | EP1613296A2 Methods for treatment of parkinson's disease |
| 01/11/2006 | EP1613295A1 Use of alkyl resorcinols in the treatment of acne |
| 01/11/2006 | EP1613288A1 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol |
| 01/11/2006 | EP1613276A1 Low viscosity liquid dosage forms |
| 01/11/2006 | EP1442036B1 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 01/11/2006 | EP1435986A4 Igf-binding protein-derived peptide or small molecule |
| 01/11/2006 | EP1414481B1 Use of cetrorelix for the treatment of jacob-creutzfeldt-disease |
| 01/11/2006 | EP1385489B1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 01/11/2006 | EP1303540B1 Multi-specific reagent for selective stimulation of cell surface receptors |
| 01/11/2006 | EP1235925B1 Feeding assay for identifying nematicidal compounds |
| 01/11/2006 | EP1179186B1 Method for identifying modulators of interacting proteins |
| 01/11/2006 | EP1047422B1 Use of histamine for elevating blood histamine levels |
| 01/11/2006 | EP0822822A4 Controlled release of miotic and mydriatic drugs in the anterior chamber |
| 01/11/2006 | CN1720326A Method of strengthening foreign epitope presentation by MHC class I by inhibiting TAP activity |
| 01/11/2006 | CN1720065A Dispersible pharmaceutical compositions |
| 01/11/2006 | CN1720064A Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 01/11/2006 | CN1720053A Method of reducing toxicity of anticancer agents |
| 01/11/2006 | CN1720045A Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases |
| 01/11/2006 | CN1720044A Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| 01/11/2006 | CN1720038A Gabapentin analogues for fibromy algia and other disorders |
| 01/11/2006 | CN1720029A Alpha-2-delta ligand to treat lower urinary tract symptoms |
| 01/11/2006 | CN1720028A Transdermal analgesic systems with reduced abuse potential |
| 01/11/2006 | CN1719975A Treatment for hemorrhagic shock |
| 01/11/2006 | CN1718244A Activated carbon external application antiphlogistine, and its prepn. method |
| 01/11/2006 | CN1235870C Novel use of phenyl hetero alkylamine derivatives |
| 01/11/2006 | CN1235641C Medicinal aerosol formulation, its preparing process, use and inhaler containing same |
| 01/11/2006 | CN1235586C Improved releasing composition and use thereof |
| 01/10/2006 | US6984667 Synergistic proteoglycan compositions for inflammatory conditions |
| 01/10/2006 | US6984664 Reduce side effect; analgesics |
| 01/10/2006 | US6984660 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes |
| 01/10/2006 | US6984650 Comprises phosphorescence and fluorescence resonance energy transfer; binding chenodeoxycholic acid to farnesoid X receptors; for regulating cholesterol absorption; for treatment of obesity |
| 01/10/2006 | US6984645 Aryl carboxylic acids and tetrazoles for treating diabetes, especially type II diabetes |
| 01/10/2006 | US6984639 such as (2S)-3,3-dimethyl-1-[2-(5-phenylpentanoyl) pyrrolidinyl]pentane-1,2-dione which has affinity for immunophilin; for treatment of neurological disorders/neurodegenerative diseases; nerve growth factors; FK binding proteins |
| 01/10/2006 | US6984633 Administering a combination of drugs including an angiotensin II receptor agonist (a tetrazole or triazole derivative) and an epoxysteroidal aldosterone receptor antagonist (an epoxy containing compound) as anticardiofibrosis agent |
| 01/10/2006 | US6984389 Administering to a cancer patient at least one treatment modality, containing a tyrosine kinase inhibitor and a purified heat shock protein to cure the cancer |
| 01/10/2006 | US6984128 Methods for enabling and stabilizing tooth movement |
| 01/10/2006 | CA2383036C Solid lipid formulations |
| 01/10/2006 | CA2373395C Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| 01/10/2006 | CA2299760C Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
| 01/10/2006 | CA2298549C Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
| 01/10/2006 | CA2214033C Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent |
| 01/10/2006 | CA2129897C Coa-it and paf inhibitors |
| 01/07/2006 | CA2511642A1 Compositions containing anti-acne agents and the use thereof |
| 01/05/2006 | WO2006002420A1 Cell-based therapies for ischemia |
| 01/05/2006 | WO2006002375A2 Method of treating ileus by pharmacological activation of cholinergic receptors |
| 01/05/2006 | WO2006002248A1 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 01/05/2006 | WO2006002050A1 Phospholipid compositions and methods for their preparation and use |
| 01/05/2006 | WO2006001471A1 Medicinal composition for promoting glucose-responsive insulin secretion |
| 01/05/2006 | WO2006000867A1 Compositions for topical treatment |
| 01/05/2006 | WO2006000564A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
| 01/05/2006 | WO2006000224A2 Compositions comprising strontium and vitamin d and uses thereof |
| 01/05/2006 | WO2006000222A2 The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| 01/05/2006 | WO2005055929A3 Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| 01/05/2006 | WO2005037192A3 Ibuprofen narcotic composition and method for making same |